Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Adults
NCT04852705Phase 3Unknown
- Sponsor
- Shenzhen Kangtai Biological Products
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of KCONVAC in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shenzhen Kangtai Biological Products. Primary endpoint: Incidence density of symptomatic COVID-19 cases. Status: unknown.
02
Drugs
KCONVAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04852705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852705.